NCT06201819

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

Liraglutide Effectiveness in Preoperative Weight-loss for Patients With Severe Obesity Undergoing Bariatric-metabolic Surgery.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Severe obesity is associated with considerable reduction of wellbeing and life expectancy. People living with severe obesity tend to die 8 to 10 years earlier. Preoperative management of patients living with severe obesity can be challenging and proper weight-loss may help obtain better outcomes and less morbidity. The effectiveness of GLP-1 analogue Liraglutide in preoperative weight-loss was evaluated in the study.

Detailed description

Objective: Determine liraglutide effectiveness for preoperative weight-loss in patients with severe obesity undergoing bariatric-metabolic surgery. Methods: It is a single center, quasi-experimental prospective before-and-after study. All patients were assigned the same pharmacological treatment with liraglutide, initiating dosing with 0.6 mg per day escalating 0.6 mg every week up to 3.0 mg. The treatment dose was delivered once daily via subcutaneous injection for 3 months (12 weeks). Weight-loss and percentage weight-loss was evaluated monthly using bioelectric impedance (BIA) final result at week 12.

Conditions

• Weight Loss
• Bariatric Surgery Candidate
• Obesity, Morbid

Interventions

Type	Name	Description
DRUG	Liraglutide injection	Liraglutide (GLP-1 analog) injection during 3 months

Timeline

• Start date: 2022-12-18
• Primary completion: 2023-03-18
• Completion: 2023-05-01
• First posted: 2024-01-11
• Last updated: 2024-01-18

Locations

1 site across 1 country: Mexico